1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574


Delayed Nasdaq Copenhagen  -  10:06 2022-06-29 am EDT
52.00 DKK    0.00%
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause 30-day mortality in all age groups.
06/20Invitation to ViroGates' investor meeting
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates announces its Interim Report for Q1, 2022: Record quarterly revenue and doubling of clinical customers

05/04/2022 | 07:27am EDT

COMPANY ANNOUNCEMENT - No. 11-2022 - Inside information - 4 May 2022

BIRKERØD, DENMARKViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Interim Report for the period 1 January 202231 March 2022, as approved by the company’s Board of Directors.

In Q1, 2022, ViroGates’ revenue was TDKK 3,197, increasing by 54% compared to Q1, 2021, which is the highest quarterly revenue recorded in the company’s history. The increase was primarily driven by COVID-19 customers following the EMA approval of suPAR-guided anakinra treatment in December 2021. The number of customers doubled to 33 from the disclosed +15 in Q4, 2021.

The COVID-19 pandemic continued to be a challenge in the traditional emergency department (ED) segment, but the focused efforts on converting COVID-19 customers to more general ED triaging were starting to show results. The net impact of COVID-19 remains uncertain.

Jakob Knudsen, CEO of ViroGates, says:“We are excited to start this year with strong revenue growth and a significant increase in the customer base - primarily within COVID-19 following the EMA approval. We believe several of the COVID-19 customers can be converted to general ED triage customers during the year as more new customers are expected to be onboarded across the markets we have entered recently.”

Financial results in Q1, 2022

The financial results in Q1, 2022, continued to show an increasing interest in the clinically relevant suPARnostic® products (Q1, 2021 results in brackets):

  • Revenue increased by 54% to TDKK 3,197 (TDKK 2,076)
  • Operating expenses decreased by -6% to TDKK -5,819 (TDKK -6,224)
  • Operating loss decreased by -25% to TDKK -3,435 (TDKK -4,600)
  • Net loss decreased by -31% to TDKK -2,966 (TDKK -4,274)
  • Cash and cash equivalents at the end of the period amounted to TDKK 10,870 (TDKK 23,562)

Business highlights in Q1, 2022

The business highlights indicate an increasing footprint in Europe:

  • Welcomed several new clinical routine customers in Germany, Spain, and Finland – announced a total of 33 customers across nine markets
  • Announced partnership with Italy-based DIESSE for the suPARnostic® ELISA product to be implemented on the Chorus Trio platform
  • Issued warrants to key non-management employees

This announcement is a summary and should be read in conjunction with ViroGates’ Interim Report for Q1, 2022, published on 4 May 2022. A downloadable PDF version will be available on the company’s website.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.


  • Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com


© Ritzau Denmark, source Ritzau English Regulatory Releases

All news about VIROGATES A/S
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
06/20Invitation to ViroGates' investor meeting
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
05/30ViroGates announces the election of Patrik Dahlen as its new chairman of the board
05/30ViroGates A/S Announces Board Changes
05/25ViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
05/25ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product,..
05/10VIROGATES : Healthy growth
More news
Sales 2021 7,66 M 1,08 M 1,08 M
Net income 2021 -17,7 M -2,49 M -2,49 M
Net cash 2021 14,9 M 2,09 M 2,09 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 165 M 23,2 M 23,2 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 52,3%
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors